Investor appetite for neurology companies could grow in 2021 - Jefferies

Zynerba Pharmaceuticals

09/11/2020 15:03

** Demand for neurology companies could pick up in 2021,
Jefferies says, citing comments made during the recent expert
panel discussion on Biogen Inc's  BIIB.O  application for its
Alzheimer's drug, aducanumab
    ** There is "a profound and enormous unmet medical need" for
new treatments for Alzheimer's, Billy Dunn, director of
neurology products for the FDA's Center for Drug Evaluation and
Research said during the meeting on Friday
    ** The health regulator's neuroscience division is becoming
more supportive and conducive in approving neurology drugs -
Jefferies
    ** While the Alzheimer's space looks poised to particularly
benefit, the tailwind could extend out to neurology more
broadly, helping companies developing drugs for conditions such
as depression and epilepsy - brokerage 
    ** Shares of companies including Athira Pharma  ATHA.O ,
Sage Therapeutics  SAGE.O , Intra-cellular Therapies  ITCI.O 
and Marinus Pharma  MRNS.O  up 2%-5% 
    

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))